Analysts expect Assembly Biosciences Inc (NASDAQ:ASMB) to report sales of $12.54 million for the current quarter, Zacks Investment Research reports. Four analysts have provided estimates for Assembly Biosciences’ earnings. The highest sales estimate is $36.04 million and the lowest is $4.00 million. Assembly Biosciences posted sales of $3.08 million in the same quarter last year, which suggests a positive year-over-year growth rate of 307.1%. The business is expected to issue its next quarterly earnings report on Monday, August 3rd.
According to Zacks, analysts expect that Assembly Biosciences will report full-year sales of $20.36 million for the current fiscal year, with estimates ranging from $10.21 million to $40.12 million. For the next year, analysts anticipate that the firm will post sales of $15.80 million, with estimates ranging from $14.00 million to $17.60 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research firms that that provide coverage for Assembly Biosciences.
Assembly Biosciences (NASDAQ:ASMB) last released its earnings results on Thursday, May 7th. The biopharmaceutical company reported ($0.76) EPS for the quarter, topping analysts’ consensus estimates of ($0.98) by $0.22. The company had revenue of $4.08 million during the quarter, compared to analysts’ expectations of $3.82 million. Assembly Biosciences had a negative net margin of 601.75% and a negative return on equity of 45.43%.
In other news, EVP Richard James Colonno sold 7,812 shares of Assembly Biosciences stock in a transaction that occurred on Tuesday, March 31st. The shares were sold at an average price of $15.04, for a total transaction of $117,492.48. Following the completion of the transaction, the executive vice president now directly owns 144,821 shares of the company’s stock, valued at approximately $2,178,107.84. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 12.42% of the stock is owned by insiders.
A number of institutional investors have recently added to or reduced their stakes in the stock. EcoR1 Capital LLC grew its stake in Assembly Biosciences by 301.5% in the 4th quarter. EcoR1 Capital LLC now owns 2,388,268 shares of the biopharmaceutical company’s stock valued at $48,864,000 after acquiring an additional 1,793,368 shares during the period. BlackRock Inc. grew its stake in Assembly Biosciences by 15.6% in the 1st quarter. BlackRock Inc. now owns 2,297,866 shares of the biopharmaceutical company’s stock valued at $34,079,000 after acquiring an additional 310,648 shares during the period. Victory Capital Management Inc. grew its stake in Assembly Biosciences by 30,224.0% in the 4th quarter. Victory Capital Management Inc. now owns 1,325,460 shares of the biopharmaceutical company’s stock valued at $27,119,000 after acquiring an additional 1,321,089 shares during the period. Franklin Resources Inc. acquired a new stake in Assembly Biosciences in the 4th quarter valued at $14,829,000. Finally, FMR LLC grew its stake in Assembly Biosciences by 328.7% in the 4th quarter. FMR LLC now owns 717,217 shares of the biopharmaceutical company’s stock valued at $14,675,000 after acquiring an additional 549,924 shares during the period. 88.34% of the stock is currently owned by hedge funds and other institutional investors.
ASMB stock traded up $0.65 during trading on Friday, reaching $23.81. The company had a trading volume of 166,900 shares, compared to its average volume of 261,602. The firm has a 50-day simple moving average of $20.86 and a 200-day simple moving average of $18.82. The company has a market cap of $757.85 million, a price-to-earnings ratio of -6.94 and a beta of 1.26. The company has a debt-to-equity ratio of 0.03, a quick ratio of 12.14 and a current ratio of 12.14. Assembly Biosciences has a twelve month low of $8.13 and a twelve month high of $25.07.
Assembly Biosciences Company Profile
Assembly Biosciences, Inc operates as a clinical-stage biotechnology company in the United States. The company develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutic candidates to treat disorders associated with the microbiome.
Read More: What causes a recession?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.